- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.06. | Biomind Labs Inc: Biomind Labs delisting review extended | 1 | Stockwatch | ||
| 21.04. | Biomind Labs Inc: Biomind cheers executive order for psychedelic research | 3 | Stockwatch | ||
| 20.04. | Biomind Labs Inc.: Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States | 352 | ACCESS Newswire | A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20... ► Artikel lesen | |
| 07.03. | Biomind Labs Inc: Biomind Labs under Cboe Canada delisting review | 2 | Stockwatch | ||
| 13.02. | Biomind Labs Inc: Biomind Labs shareholders approve all matters at AGSM | 1 | Stockwatch | ||
| BIOMIND LABS Aktie jetzt für 0€ handeln | |||||
| 27.01. | Biomind Labs Inc.: Biomind Labs Announces CAD $2.52 Million Private Placement Financing | 425 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / January 27, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 27.01. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 27.01.2026 | 173 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 27.01.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 27.01.2026ISIN NameDE000HEL0GB7 LB.HESS.THR.CARRARA04S/25XS2576250448... ► Artikel lesen | |
| 03.12.25 | Biomind Labs Inc.: Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood | 361 | ACCESS Newswire | BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 01.12.25 | XFRA 3XI: WIEDERAUFNAHME/RESUMPTION | 248 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 25.11.25 | Biomind Labs Inc.: Biomind Labs Announces Revocation of Cease Trade Order | 479 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 25, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that the Ontario Securities Commission (the "Commission") has revoked... ► Artikel lesen | |
| 18.11.25 | Biomind Labs Inc.: Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board | 507 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 18, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that it has filed the following continuous disclosure documents... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AAP IMPLANTATE | 1,930 | +1,58 % | EQS-HV: aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: aap Implantate AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin... ► Artikel lesen | |
| CLEARMIND MEDICINE | 3,740 | -1,32 % | Clearmind Medicine Inc.: Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment | Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development... ► Artikel lesen | |
| TANGO THERAPEUTICS | 30,940 | +0,03 % | Tango Therapeutics stock soars on promising pancreatic cancer data | ||
| NURIX THERAPEUTICS | 15,640 | 0,00 % | Biotech-Partnerschaft: Roche greift zu: Dieser Milliarden-Deal lässt Anleger aufhorchen | © Foto: Vladimir Borovic - Adobe StockRoche steigt mit einem milliardenschweren Deal bei Nurix ein. Im Fokus steht ein vielversprechender Wirkstoff gegen Krebs, Autoimmun- und Nervenkrankheiten.Der... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,110 | 0,00 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| COGENT BIOSCIENCES | 31,160 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 82,94 | -0,08 % | RBC Capital raises Apogee Therapeutics stock price target to $97 | ||
| PRAXIS PRECISION MEDICINES | 253,12 | -0,05 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ERASCA | 12,870 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,780 | 0,00 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| AMYLYX PHARMACEUTICALS | 13,010 | 0,00 % | H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights | ||
| KINIKSA PHARMACEUTICALS | 49,040 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 22,500 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,000 | 0,00 % | Pictet closes $1.53bn Monte Rosa Co-Investments VI fund, exceeding target | ||
| DYNE THERAPEUTICS | 16,820 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) | - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage... ► Artikel lesen |
Das Unternehmen BIOMIND LABS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,037 Euro und damit -8,75 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMIND LABS INC finden Sie auf Wallstreet Online.